Stoke Therapeutics Valuation
| STOK Stock | USD 32.40 1.92 6.30% |
At this time, the company appears to be undervalued. Stoke Therapeutics has a current Real Value of $36.52 per share. The regular price of the company is $32.4. Our model measures the value of Stoke Therapeutics from inspecting the company fundamentals such as Operating Margin of (4.05) %, return on equity of 0.15, and Shares Outstanding of 57.12 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Stoke Therapeutics' valuation include:
Price Book 6.0045 | Enterprise Value | Enterprise Value Ebitda 55.1663 | Price Sales 8.9996 | Forward PE 204.0816 |
Undervalued
Today
Please note that Stoke Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Stoke Therapeutics is based on 3 months time horizon. Increasing Stoke Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Stoke Therapeutics' intrinsic value may or may not be the same as its current market price of 32.40, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 32.4 | Real 36.52 | Target 41.89 | Hype 31.9 |
The intrinsic value of Stoke Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Stoke Therapeutics' stock price.
Estimating the potential upside or downside of Stoke Therapeutics helps investors to forecast how Stoke stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Stoke Therapeutics more accurately as focusing exclusively on Stoke Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Stoke Therapeutics' intrinsic value based on its ongoing forecasts of Stoke Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Stoke Therapeutics' closest peers.
Stoke Therapeutics Cash |
|
Stoke Therapeutics Total Value Analysis
Stoke Therapeutics is at this time estimated to have valuation of 1.6 B with market capitalization of 1.85 B, debt of 2.32 M, and cash on hands of 275.63 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Stoke Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.6 B | 1.85 B | 2.32 M | 275.63 M |
Stoke Therapeutics Investor Information
About 96.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.27. Stoke Therapeutics had not issued any dividends in recent years. The entity had 1:9 split on the 6th of June 2019. Based on the key indicators related to Stoke Therapeutics' liquidity, profitability, solvency, and operating efficiency, Stoke Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Stoke Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Stoke Therapeutics has an asset utilization ratio of 13.46 percent. This suggests that the Company is making $0.13 for each dollar of assets. An increasing asset utilization means that Stoke Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Stoke Therapeutics Profitability Analysis
Based on Stoke Therapeutics' profitability indicators, Stoke Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Stoke Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2018-03-31 | Previous Quarter -23.5 M | Current Value -38.3 M | Quarterly Volatility 25.3 M |
For Stoke Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Stoke Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Stoke Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Stoke Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Stoke Therapeutics over time as well as its relative position and ranking within its peers.
Stoke Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Stoke Therapeutics is estimated to be -0.7764 with future projections ranging from a low of -0.875 to a high of -0.6975. Stoke Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at 0.68. Please be aware that the consensus of earnings estimates for Stoke Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Stoke Therapeutics Earnings Estimation Breakdown
The calculation of Stoke Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Stoke Therapeutics is estimated to be -0.7764 with the future projection ranging from a low of -0.875 to a high of -0.6975. Please be aware that this consensus of annual earnings estimates for Stoke Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.88 Lowest | Expected EPS | -0.7 Highest |
Stoke Therapeutics Earnings Projection Consensus
Suppose the current estimates of Stoke Therapeutics' value are higher than the current market price of the Stoke Therapeutics stock. In this case, investors may conclude that Stoke Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Stoke Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 11 | 41.27% | 0.0 | -0.7764 | 0.68 |
Stoke Therapeutics Ownership Allocation
The majority of Stoke Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Stoke Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Stoke Therapeutics. Please pay attention to any change in the institutional holdings of Stoke Therapeutics as this could imply that something significant has changed or is about to change at the company.Stoke Therapeutics Profitability Analysis
The company reported the previous year's revenue of 36.55 M. Net Loss for the year was (88.98 M) with profit before overhead, payroll, taxes, and interest of 205.63 M.About Stoke Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Stoke Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Stoke Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Stoke Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Stoke Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Stoke Therapeutics. We calculate exposure to Stoke Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Stoke Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 42 M | 44.1 M | |
| Pretax Profit Margin | (2.19) | (2.30) | |
| Operating Profit Margin | (2.50) | (2.62) | |
| Net Loss | (2.19) | (2.30) |
Stoke Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Stoke Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 54 M | |
| Forward Price Earnings | 204.0816 |
Stoke Therapeutics Current Valuation Indicators
Stoke Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Stoke Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Stoke Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Stoke Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Stoke Therapeutics' worth.When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Stoke Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.68 | Revenue Per Share | Quarterly Revenue Growth 1.172 | Return On Assets | Return On Equity |
Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.